REPORT

Type II collagen degradation and its regulation in articular cartilage in osteoarthritis

A R Poole¹, M Kobayashi^1,2, T Yasuda^1,2, S Laverty^1,3, F Mwale⁴, T Kojima^1,5, T Sakai¹, C Wahl¹, S El-Maadawy¹, G Webb⁶, E Tchetina¹, W Wu⁷

¹ Shriners Hospitals for Children, Departments of Surgery and Medicine, McGill University, Montreal, Quebec, Canada
² Department of Orthopaedic Surgery, Kyoto University Medical School, Kyoto, Japan
³ Faculty of Veterinary Medicine, Department of Clinical Sciences, University of Montreal, Ste-Hyacinthe, Quebec, Canada
⁴ Department of Orthopaedic Surgery, Jewish General Hospital, Montreal, Quebec, Canada
⁵ Department of Orthopaedic Surgery, Nagoya University School of Medicine, Nagoya, Japan
⁶ Molecular Cell Biology Unit, Glaxo Wellcome Research, Stevenage, Hertfordshire, UK
⁷ Arthritis Unit, Massachusetts General Hospital, Boston, MA, USA

Correspondence to:
Correspondence to:
Dr A R Poole;
rpoole@shriners.mcgill.ca

Keywords: collagen; articular cartilage; osteoarthritis

Abbreviations: IL, interleukin; JSN, joint space narrowing; MMP, matrix metalloproteinase; OA, osteoarthritis; RA, rheumatoid arthritis, TGFß, transforming growth factor ß; TNF, tumour necrosis factor

The first 150 words of the full text of this article appear below.

The progressive degeneration of articular cartilage is an underlying problem in the pathogenesis of osteoarthritis (OA) as well as in rheumatoid arthritis (RA) and other inflammation arthritides. It leads to a loss of joint function, frequently accompanied by debilitating pain.

In idiopathic OA this is a degenerative process that may cover a period of 20–30 years, culminating in clinical presentation and a need for joint replacement as the only effective means of managing this condition. There are as yet no recognisable disease modifying treatments for OA; only symptomatic treatment (pain relief) is possible.

The physical and economic burden of OA is enormous, affecting up to 15% of the total population (>50% of the aging population over 60 years of age). We face an enormous challenge in the management of this condition. Yet with recent progress in reaching an improved understanding of the pathobiology of this condition there is a realisation . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• DONG, W., ZHANG, Y., LIU, H., GAO, B., LI, D., YANG, J. (2009). Detection of Unsaturated Disaccharides, Pyridinoline, and Hydroxyproline in Urine of Patients with Kashin-Beck Disease: Comparison with Controls in an Endemic Area. The Journal of Rheumatology 36: 816-821 [Abstract] [Full Text]  
• Zhang, Q, Hui, W, Litherland, G J, Barter, M J, Davidson, R, Darrah, C, Donell, S T, Clark, I M, Cawston, T E, Robinson, J H, Rowan, A D, Young, D A (2008). Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 67: 1633-1641 [Abstract] [Full Text]  
• Meulenbelt, I, Kloppenburg, M, Kroon, H M, Houwing-Duistermaat, J J, Garnero, P, Hellio Le Graverand, M-P, DeGroot, J, Slagboom, P E (2006). Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 65: 360-365 [Abstract] [Full Text]